A literature review was conducted on adverse events related to IOI after administration of brolucizumab in eyes with neovascular age-related macular degeneration.
Possible risk factors for IOI and retinal vascular occlusion after brolucizumab should be considered before administering brolucizumab. Patients who receive brolucizumab should be educated on the symptoms, signs, and time course of IOI after brolucizumab. Before each injection of brolucizumab, physicians should assess the eye for any signs of inflammation and not treat with brolucizumab if inflammation is detected. Treatment of IOI should be prompt and provided with particular attention to the posterior segment.
Careful patient selection, patient education, assessment for inflammation, and intensive treatment of possible inflammation are important when using brolucizumab in patients with neovascular age-related macular degeneration.
对患有新生血管性年龄相关性黄斑变性的眼用Brolucizumab后与IOI相关的不良事件进行了文献综述。
在使用brolucizumab之前,应考虑brolucizumab后IOI和视网膜血管阻塞的可能危险因素。接受brolucizumab的患者应接受症状教育,标志,以及Brolucizumab治疗后IOI的时程。在每次注射brolucizumab之前,医师应评估眼部是否有任何炎症迹象,如果发现炎症,则不应使用brolucizumab治疗.IOI的治疗应迅速进行,并特别注意后段。
精心挑选病人,患者教育,炎症评估,在新生血管性年龄相关性黄斑变性患者中使用brolucizumab时,对可能的炎症进行强化治疗非常重要。